Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N3WN
|
|||
| Former ID |
DNCL002002
|
|||
| Drug Name |
ABT-308
|
|||
| Indication | Eosinophilic esophagitis [ICD-11: DA24.1; ICD-9: 530.13] | Phase 2 | [1] | |
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 1 | [2] | ||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 13 receptor alpha-2 (IL13RA2) | Target Info | Antagonist | [1] |
| KEGG Pathway | Jak-STAT signaling pathway | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT00986037) Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.